Wasatch Advisors’s Inovio Pharmaceuticals INO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-410,510
| Closed | -$24.6M | – | 268 |
|
|
2021
Q4 | $24.6M | Buy |
410,510
+111,540
| +37% | +$8.94M | 0.1% | 160 |
|
|
2021
Q3 | $25.7M | Buy |
298,970
+911
| +0.3% | +$91.4K | 0.1% | 155 |
|
|
2021
Q2 | $33.2M | Buy |
298,059
+32,086
| +12% | +$3.08M | 0.13% | 142 |
|
|
2021
Q1 | $29.6M | Sell |
265,973
-62,279
| -19% | -$8.19M | 0.13% | 133 |
|
|
2020
Q4 | $34.9M | Buy |
328,252
+46,335
| +16% | +$6.17M | 0.17% | 111 |
|
|
2020
Q3 | $39.2M | Buy |
281,917
+105,548
| +60% | +$22M | 0.25% | 97 |
|
|
2020
Q2 | $57M | Sell |
176,369
-123,698
| -41% | -$19.9M | 0.41% | 77 |
|
|
2020
Q1 | $26.8M | Sell |
300,067
-323,502
| -52% | -$19.9M | 0.28% | 82 |
|
|
2019
Q4 | $24.7M | Buy |
623,569
+70,023
| +13% | +$2.11M | 0.2% | 100 |
|
|
2019
Q3 | $13.6M | Sell |
553,546
-7,765
| -1% | -$236K | 0.13% | 120 |
|
|
2019
Q2 | $19.8M | Buy |
561,311
+73,943
| +15% | +$2.94M | 0.19% | 105 |
|
|
2019
Q1 | $21.8M | Buy |
487,368
+42,540
| +10% | +$2.14M | 0.24% | 83 |
|
|
2018
Q4 | $21.4M | Buy |
444,828
+47,505
| +12% | +$2.89M | 0.28% | 80 |
|
|
2018
Q3 | $26.5M | Buy |
397,323
+169,140
| +74% | +$9.42M | 0.3% | 77 |
|
|
2018
Q2 | $10.7M | Buy |
228,183
+14,576
| +7% | +$804K | 0.13% | 110 |
|
|
2018
Q1 | $12.1M | Sell |
213,607
-8,434
| -4% | -$456K | 0.16% | 101 |
|
|
2017
Q4 | $11M | Sell |
222,041
-2,237
| -1% | -$139K | 0.15% | 114 |
|
|
2017
Q3 | $17.1M | Buy |
224,278
+6,710
| +3% | +$499K | 0.23% | 91 |
|
|
2017
Q2 | $20.5M | Buy |
217,568
+66,109
| +44% | +$5.65M | 0.29% | 80 |
|
|
2017
Q1 | $12M | Sell |
151,459
-2,269
| -1% | -$181K | 0.18% | 100 |
|
|
2016
Q4 | $12.8M | Sell |
153,728
-1,401
| -0.9% | -$127K | 0.19% | 100 |
|
|
2016
Q3 | $17.4M | Sell |
155,129
-1,217
| -0.8% | -$134K | 0.26% | 92 |
|
|
2016
Q2 | $17.3M | Sell |
156,346
-1,434
| -0.9% | -$174K | 0.27% | 91 |
|
|
2016
Q1 | $16.3M | Sell |
157,780
-3,743
| -2% | -$289K | 0.25% | 106 |
|
|
2015
Q4 | $13M | Buy |
161,523
+1,697
| +1% | +$135K | 0.18% | 130 |
|
|
2015
Q3 | $11.1M | Sell |
159,826
-3,434
| -2% | -$299K | 0.15% | 153 |
|
|
2015
Q2 | $16M | Buy |
163,260
+3,151
| +2% | +$337K | 0.17% | 152 |
|
|
2015
Q1 | $15.7M | Buy |
160,109
+2,408
| +2% | +$233K | 0.16% | 138 |
|
|
2014
Q4 | $17.4M | Buy |
157,701
+146,444
| +1,301% | +$17.9M | 0.18% | 128 |
|
|
2014
Q3 | $1.33M | Buy |
11,257
+9,379
| +499% | +$1.17M | 0.01% | 341 |
|
|
2014
Q2 | $244K | Buy |
+1,878
| New | +$222K | ﹤0.01% | 384 |
|
Other funds holding INO
Wasatch Advisors's INO Position: Q1 2022 in Review
Wasatch Advisors sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 410,510 shares — an estimated $24.6M sold.
Wasatch Advisors first reported a position in INO in Q2 2014 and held it in 31 quarters. The position peaked at $57M in Q2 2020. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.
- Wasatch Advisors reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
- Wasatch Advisors sold 410,510 Inovio Pharmaceuticals shares in Q1 2022, an estimated $24.6M.
- Wasatch Advisors first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 31 quarters.
- Wasatch Advisors's Inovio Pharmaceuticals position peaked at $57M in Q2 2020.
- 198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.
Based on Wasatch Advisors's 13F filing for Q1 2022, filed 13 May 2022.